Protective effect of N-acetylcysteine on anti tuberculosis drug-induced hepatotoxicity Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB) Source: Annual Congress 2007 - Epidemiology of tuberculosis II Year: 2007
Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity Source: International Congress 2015 – Screening strategies in TB Year: 2015
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
The influence phenotype of hydroxylation on anti-tuberculosis drug-induced hepatotoxicity Source: Eur Respir J 2006; 28: Suppl. 50, 505s Year: 2006
Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Protective effect of oral erdostein administration on cisplatin-induced nephrotoxicity in rats Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Chloroquine as a potential adjunctive therapy in tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Effect of N-acetylcysteine on the activity of antibiotics against relevant respiratory pathogens Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Manifestations of hypersensitivity to anti-tuberculosis drugs Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018
Antituberculotic drug-induced medicamentous liver damages Source: Eur Respir J 2004; 24: Suppl. 48, 51s Year: 2004
Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008
Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia : A cohort study Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016
Treatment of patients with extensive TB and concomitant bronchial lesions with some anti-TB drugs delivered via nebulizer Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD) Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016